Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...

Content from other channels on our network

Making Australian canola oil more sustainable with solar power

Who will pay for emission reductions in the milk sector?

Fonterra charts progress against its 'Climate Roadmap'

How to manage safety risks in the low-moisture food sector?

Pure Dairy appoints new CCO

Rising healthcare facility demands pave way for innovation

Designs unveiled for the new Melton Hospital

AIA Australia launches virtual mental health service

Depressive disorders: 70% of Australians not getting adequate treatment

High blood pressure costs Australia $1.2bn a year

Making the national electricity market fit for purpose

Driving progress in clean energy

A first line of defence in wastewater screening

NSW initiative tackles food waste at the source

NSW celebrates recycling triumph